Use of A3 adenosine receptor agonist in osteoarthritis treatment

摘要

Provided is an A₃ adenosine receptor agonist (A₃AR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method includes administering to said subject in need of said treatment an amount of A₃AR agonist, the amount being effective to treat or prevent the development of OA. Preferred but not exclusive A₃AR agonists in accordance with the present subject matter are IB-MECA and Cl-IB-MECA. The A₃AR agonist may be administered in combination with another drug, such as Methotrexate (MTX). Also provided are pharmaceutical compositions for treatment of osteoarthritis including an amount of an A₃AR agonist.